Member Info for goupplease

Randoml I liked what I see in the old days,at the time I wasn't aware dan was not a negotiationer ,
I think I have learnt that and admit I fell for his podcast,
The fact the bod have a lot of skin in here is the thing that keeps me going ,
I hope karl keegan can bring his experience to the game,
I think they have drawn a line and we are seeing a new beginning,
Personally I don't think after all this time we have a Japan deal ,covid gives them an excuse , nothing happens quickly ,in the old days we were a year behind predicted schedule. But you can't keep promising jam tomorrow it catches up on you ,for 9 months schedule has been missed and that's poor , like I say I hope karl keegan points Dan in the right direction to date we have ebers and the new company,
Dan always boasts have quick the method is but produced nowt ,
You can only live on what's a positive rns and the market don't go on his uncertainty,
We are just about the worst performing pharma at present

Let's hope karl keegan can see through dans mess and come up with the goods:
Dans lab material , don't let him loose ever again on a podcast .
Not one word has come good

Agreed random , no rns needed,
I acknowledge I have made mistakes backing a Dan led nfx, his podcast turned out rotten to the core ,
Hope he's been sorted, the Japan deal is as dead as his China one imho
Talk about a podcast ramp , we are main market , leave it alone , close ?it was never on .

The company has drawn a line ,all the deals to date have failed ,
The are actively looking for new business ,
It's said many times Dan not up to closure ,
We have the men now who can , we done want anymore of dans bull**** , we want proper pr served in a proper manner.

PR spells imformation out ,don't leave it hanging ,
Nfx pr is not good,
We need a new shop window .
I ask anybody whom satisfied with pr , put your hand up

Halespur , no company was act mentioned in the price movement rns.
All the Japan deal has been newspaper and bb led so surely an rns is not essential.
Too much time has elapsed approx 7 months , the deal should have been down to dotting the I crossing the t's even with covI'd 19 .you're clinging to straws
My feeling that deal is as dead as China. I'm not saying something else is on thr horizon,
Nuformix has established a broader range of assets, opportunities and revenue sources that ought to mitigate such risks. From the rns ,
The company's floundering under the old bod , the new bod needs to draw a line quickly , so much has gone out the window ,
You can have a good scientists but when it comes to pr and financial they are out their depths, that it what we have seen here , Dan is not the right man to take this company fowards , Karl keegan is . Afraid I have not got years waiting,

To keep #Nuformix in the UK with patents .
For me the Japenese deal is dead and China deader.

LONDON (Reuters) - Respiratory drug specialist Vectura (VEC.L) has agreed to buy rival SkyePharma SKP.L for 441 million pounds ($621 million), in a notable piece of consolidation among Britain’s universe of small biotech companies.

The tie-up will create a lung disease group with expertise across different ____inhaler technologies____ and a combined market value of more than 1 billion pounds, which should attract a wider range of institutional investors.

Unlike large, successful biotechnology firms in the United States, British firms have yet to achieve critical mass and, as a result, have often struggled to secure an active following from investors and analysts.

“I would expect to see a number of new holders coming into this stock, given our mid-cap market capitalization with the combination,” said James Ward-Lilley, Vectura’s chief executive, who will become CEO of the enlarged group.

“We have today really got the opportunity to be an industry leader in terms of the device and technology focused on inhaled respiratory airway disease.”

ADVERTISEMENT

If #tils are going to market quickly with StemprintER they are only going to go to one exchange if they are disposing , will that be a clue , ?

Vectura and Skyepharma want the Nuformix patents ,
Maybe Dr Karl Keegan is the magic link ,
Sounds like the pharma tech is closely linked .
Maybe they need what nuformix offer?

Credit to willowman19, I don't want this hidden.
https://ir.vistagen.com/press-releases/detail/140/vistagen-and-nuformix-announce-agreement-to-develop-novel

Highly motivated, accomplished, senior Investor Relations and Corporate Communications Executive. Proficient and natural communicator with a wealth of experience gained within UK investment banking and life sciences sector. Driven and ambitious with a business focused approach and strategic leadership experience including M&A, Corporate Development, business transformation and integrations.
Would

Well spotted

And it's not a one trick pony , #tils have so much on the table ,
The existing company could be worth more ,
£££££££££

Cheers dreamchase back to the classroom for me !

I can't afford the ft !

$6.85 after hours trading. £1.37 if my maths are right

Big supporter

https://twitter.com › Nuformixplc
NFX (@NuformixPlc) | Twitter.
Nfx don't take advantage of twitter, pr is so important,

Please read Willowman19 very good post , it needs highlighting before it gets buried